Abpro Q3 2025 Earnings Report

Abpro EPS Results

• Actual EPS: -$0.63
• Consensus EPS: -$1.20
• Beat/Miss: Beat by +$0.57
• One Year Ago EPS: N/A

Abpro Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Abpro Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Abpro (NASDAQ:ABP) is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company uses its proprietary DiversImmune platform to discover and engineer next-generation antibodies, including bispecific antibodies designed to engage the immune system and target disease-associated proteins.

Abpro’s lead product candidate is ABP-100, a bispecific antibody designed to bind HER2 on tumor cells and CD3 on T cells. The company is evaluating ABP-100 as a potential treatment for HER2-expressing cancers. Its broader pipeline includes additional antibody programs at various stages of development.

Abpro operates as a biotechnology company serving the global biopharmaceutical market, with research and development activities focused on advancing its proprietary antibody platform and therapeutic candidates. The company is led by co-founder and Chief Executive Officer Ian Chan and became publicly traded on the Nasdaq under the symbol ABP following a business combination in 2024.